Pfizer Inc. (PFE) Announces FDA’s Grant of Priority Review for HYMPAVZI® (marstacimab) sBLA

Pfizer Inc. (NYSE:PFE) is one of the best healthcare stocks under $50 to invest in. Pfizer Inc. (NYSE:PFE) announced on ...
Hosted on MSN

Pfizer's stock just dropped 6%. Can the pharmaceutical giant bounce back in 2026?

Promising clinical results in 2026 could set the stage for Pfizer's stock to rebound. However, the company's COVID-19 product and patent cliff challenges could prevent a big bounce this year. Even if ...
The Motley Fool

Where Will Pfizer Be in 3 Years?

Pfizer has a long history of success in the competitive and complex drug sector. The pharmaceutical giant has patent expirations coming in 2027 and 2028. Management's attempt to solve the issue has ...
Seeking Alpha

Pfizer: 2026 Guidance Points To Continued Margin And Growth Pressure

I last covered Pfizer Inc. stock (PFE) on Nov 8, 2025, with an article titled "Healthcare Q3 Dividend Roundup: I Prefer AbbVie Over Pfizer". The article mainly served as a review for the company's FQ3 ...
Rolling Out

Pfizer beats Q3 estimates by impressive 32%

Pfizer delivered a significant earnings surprise in its third-quarter results, demonstrating the pharmaceutical giant’s resilience amid a challenging year for its stock performance. The company’s ...
Forbes

Pfizer Bets Big On Obesity Market

Pfizer $4.9 billion cash acquisition of Metsera, a clinical-stage biotech focused on next-generation obesity drugs, is more than another high-profile deal in pharma’s dealmaking spree. It signals a ...
The Motley Fool

Where Will Pfizer Be in 5 Years?

Pfizer's stock soared during the coronavirus pandemic because of its COVID-19 vaccine. The world has learned to live with the coronavirus, and Pfizer's stock has plunged as a result. Faced with patent ...